Towa Pharma Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 25-06-2024
- Paid Up Capital ₹ 3.95 Cr
as on 25-06-2024
- Company Age 6 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 8.16 Cr
as on 25-06-2024
- Revenue 50.72%
(FY 2021)
- Profit -1141.76%
(FY 2021)
- Ebitda -671.59%
(FY 2021)
- Net Worth
- Total Assets 121.13%
(FY 2021)
About Towa Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 3.95 Cr.
The company currently has active open charges totaling ₹8.16 Cr.
Himank Shah, Nayanaben Shah, Anil Vishwambhardayal, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24100GJ2018PTC101736
- Company No.
101736
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Apr 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Towa Pharma?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Himank Shah  | Director | 10-Apr-2018 | Current |
| Nayanaben Shah | Director | 25-Aug-2023 | Current |
| Anil Vishwambhardayal | Director | 10-Apr-2018 | Current |
| Vimalkumar Gupta | Director | 10-Apr-2018 | Current |
| Prashant Srivastava | Director | 17-May-2019 | Current |
| Pradip Srivastava | Director | 17-May-2019 | Current |
Financial Performance of Towa Pharma.
Towa Pharma Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 50.72% increase. The company also saw a substantial fall in profitability, with a 1141.76% decrease in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth | |||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Towa Pharma?
Unlock access to Towa Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Zynex Lifescience LlpActive 7 years 9 months
Himank Shah, Anil Vishwambhardayal and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 07 Sep 2020 | ₹8.16 Cr | Open |
How Many Employees Work at Towa Pharma?
Unlock and access historical data on people associated with Towa Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Towa Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Towa Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
